Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
February 11 2019 - 7:57AM
Dow Jones News
By Michael Dabaie
Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNY) said
Monday they will offer Praluent at a reduced U.S. list price.
Praluent will be available at a reduced U.S. list price of
$5,850 annually, a 60% reduction from the original price, for both
the 75 mg and 150 mg doses, beginning in early March.
With the new lower-priced Praluent, most Medicare Part D
patients are expected to pay between $25 to $150 per month,
depending on their insurance plan, the companies said. Praluent is
a treatment for adults with heterozygous familial
hypercholesterolemia or clinical atherosclerotic cardiovascular
disease.
The companies in March 2018 committed to lower the U.S. net
price for payers in return for helping to reduce access barriers
for appropriate patients, the companies said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
February 11, 2019 07:42 ET (12:42 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024
